Zepbound for sleep apnea: who qualifies and who pays

Zepbound is FDA-approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, and on December 20, 2024 it became the first medication approved for the condition. It’s a weekly injection, taken at a maintenance dose of 10 mg or 15 mg alongside a reduced-calorie diet and more physical activity.

Sleep apnea also changes how Zepbound gets paid for. Medicaid programs must cover it for this use, Medicare Part D plans can, and commercial plans write separate criteria for it. Below is who qualifies, what the trials found, and what each type of coverage asks for.

What the FDA approved

The Zepbound label (revised August 2026) lists two uses, both with a reduced-calorie diet and increased physical activity:

• reducing excess body weight and keeping it off long term, in adults with obesity or adults with overweight and at least one weight-related condition
• treating moderate to severe OSA in adults with obesity

In OSA, the upper airway closes during sleep, so breathing stops or turns shallow over and over. Doctors measure it with the apnea-hypopnea index (AHI), the number of those events per hour on a sleep study. The label’s trials defined moderate OSA as an AHI of 15 to 30 and severe OSA as 30 or more, and they enrolled adults with a BMI of 30 or more.

The FDA said the improvement in AHI is likely related to the weight people lost on Zepbound. Zepbound is tirzepatide. Mounjaro contains tirzepatide too, but its label covers type 2 diabetes, not sleep apnea.

Tirzepatide and sleep apnea: what SURMOUNT-OSA found

The approval rests on two 52-week trials of 469 adults without type 2 diabetes, published in the New England Journal of Medicine in 2024. Study 5 enrolled people who couldn’t or wouldn’t use positive airway pressure (PAP), such as a CPAP machine. Study 6 enrolled people already on PAP, who paused it for 7 days before the final sleep study. Participants took Zepbound at their highest tolerated dose, 10 mg or 15 mg, or a placebo.

Figures are from section 14.2 of the label. “Remission or mild OSA without symptoms” means an AHI under 5, or 5 to 14 with an Epworth sleepiness score of 10 or less. People on Zepbound also had larger drops in systolic blood pressure and in hsCRP, a marker of inflammation, than people on placebo.

The label adds one caution for PAP users: the trials didn’t test when, or whether, stopping PAP is appropriate for people who were using it well. Keep using your device unless your sleep doctor changes the plan.

Who qualifies

On the label, you qualify if you’re an adult with obesity and moderate to severe OSA. Insurers and Medicaid programs turn that into a checklist. Three published examples:

Scroll sideways to see the full table

Renewals usually ask for proof that it’s working. West Virginia wants a dose of at least 10 mg, better OSA symptoms, and at least 5% weight loss reached or kept. Louisiana asks for 5% weight loss (or a reason it wasn’t reached) and records from at least 3 months of follow-up showing a lower AHI and fewer symptoms.

Before your clinician files a request, gather a sleep study from the past year, a recent BMI (check yours with our BMI calculator) and notes on any CPAP use.

The dose for sleep apnea

You start at 2.5 mg once a week for 4 weeks, then step up by 2.5 mg no sooner than every 4 weeks. For sleep apnea, the label’s maintenance dose is 10 mg or 15 mg a week, against 5 mg, 10 mg or 15 mg for weight loss. Reaching 10 mg takes at least 12 weeks; in the trials, the step-up lasted up to 20 weeks.

Will insurance cover Zepbound for sleep apnea?

Sometimes, and the diagnosis on the prescription matters.

Commercial plans. Each plan writes its own criteria, like the Jefferson form above. If yours covers the single-dose pen, Lilly’s savings card can cut the cost to as little as $25 a month, with monthly and annual limits. People with government insurance can’t use it. Ask your plan whether Zepbound is covered for OSA, what the prior authorization needs, and which format it pays for. Our guide to whether insurance covers Zepbound goes plan by plan.

Does Medicare cover Zepbound for sleep apnea?

Not through the $50 Bridge. Medicare.gov says people with moderate to severe sleep apnea aren’t eligible for the Medicare GLP-1 Bridge, “but your Part D plan might cover your GLP-1s.” The CMS prior authorization form calls OSA a Part D eligible diagnosis and tells prescribers to send those requests to the patient’s Part D plan, and LillyDirect says the same about Zepbound prescribed for OSA.

So your cost depends on your plan: whether Zepbound is on its drug list, its tier, your deductible and its prior authorization rules. Lilly’s savings card excludes Medicare. The Bridge’s $50 copay applies only to weight-loss prescriptions, and for Zepbound only to the KwikPen. Our Medicare guide covers the Bridge.

Does Medicaid cover Zepbound for sleep apnea?

Yes, within each state’s criteria. KFF explains that states may choose whether to cover drugs for weight loss, but coverage of Zepbound for sleep apnea has been required since December 2024, as it is for diabetes and heart uses. Even California, which ended weight-loss GLP-1 coverage on January 1, 2026, reviews Zepbound requests for OSA case by case (Medi-Cal Rx, updated April 6, 2026). See our guides to Medicaid GLP-1 coverage by state and Medi-Cal.

What Zepbound costs without coverage

These are LillyDirect’s self-pay prices for vials and the KwikPen, read on October 27, 2026. A month is 4 single-dose vials or 1 KwikPen holding 4 weekly doses.

At the sleep apnea doses of 10 mg or 15 mg, that’s $449 a month if you refill within 45 days and $699 if you refill later. Thirteen fills on the standard step-up to 10 mg come to $5,637 refilled on time, or $8,187 refilled late each time. Lilly asks self-pay buyers to certify that the prescription is for an approved use consistent with the label, and sleep apnea is one. Our Zepbound cost guide has the full breakdown.

Online programs can write the prescription: 8 of the 26 programs we rank prescribe Zepbound, and their prices and fees vary widely. Compare them on our Zepbound program rankings. An online weight-loss visit doesn’t include a sleep study, though, so if you want insurance to pay for the OSA use, you’ll need a diagnosis from a sleep test first.

Compounded tirzepatide isn’t approved for sleep apnea

Compounded tirzepatide is not Zepbound and not a generic of it. A compounding pharmacy prepares it, it isn’t FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness or quality (FDA). The SURMOUNT-OSA results were measured with Zepbound itself, and the Medicaid and insurer criteria above name Zepbound. Our compounded tirzepatide vs Zepbound guide covers the differences.

Safety

Boxed warning: risk of thyroid C-cell tumors. Tirzepatide causes thyroid C-cell tumors in rats, and it’s unknown whether Zepbound causes them, including medullary thyroid carcinoma (MTC), in humans. Don’t use Zepbound if you or a family member has had MTC, or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2).

The label’s other warnings cover severe stomach and bowel side effects, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar when used with insulin or sulfonylureas, worsening diabetic eye disease in people with type 2 diabetes, and inhaling stomach contents under anesthesia or deep sedation. Tell your clinician about any planned procedure.

The most common side effects, in 5% or more of people, are nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic reactions, burping, hair loss and acid reflux. If you take birth control pills, the label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after you start and after each dose increase. Zepbound may harm an unborn baby, so stop it if you become pregnant. Our guide to Zepbound side effects covers what helps.

The bottom line

Zepbound was the first drug approved for moderate to severe obstructive sleep apnea, for adults with obesity, at a maintenance dose of 10 mg or 15 mg a week. In its trials, it cut breathing events by half or more and helped 42% to 50% of people reach remission or mild OSA without symptoms.

The OSA diagnosis is what opens coverage: Medicaid must cover it, Medicare sends it to your Part D plan rather than the Bridge, and commercial plans often want a sleep study with an AHI of 15 or more and a BMI of 30 or more. Without coverage, the sleep apnea doses cost $449 a month at LillyDirect with refills within 45 days. Bring your sleep study and BMI to a licensed clinician, and see our weight-loss hub for more options.